Memic Innovative Surgery Ltd.
MedTech Acquisition Corp
Karim Karti will serve as Chairman of our board of directors upon the effective date of the registration statement of which this prospectus forms part. Mr. Karti is a highly experienced healthcare executive. He was the Chief Operating Officer of iRhythm Technologies, Inc. (Nasdaq: IRTC), a digital healthcare company, from July 2018 until March 2020, and was instrumental in launching new products and developing alliances with leading industry participants, including Verily Life Sciences, LLC, a subsidiary of Alphabet Inc. Mr. Karti previously was an officer of General Electric Company (NYSE: GE) (“GE”), where he worked for 22 years and most recently served as President and Chief Executive Officer of the GE Healthcare Imaging division from 2016 to 2018. He also served as Chief Marketing Officer for the GE Healthcare division from 2012 to 2015, as well as the President and Chief Executive Officer of GE Healthcare Emerging Markets and GE Healthcare Korea from 2009 to 2012. Mr. Karti initially was a member of the corporate audit and M&A teams at GE from 1996 to 2000, and started his career with The Procter & Gamble Company (NYSE: PG) in Brand Management in 1993. He received his undergraduate degree from Ecole Centrale de Lyon and completed the entrepreneurship program at Ecole Superieure de Commerce de Lyon in 1992. Our board has determined that Mr. Karti’s significant experience as a public company healthcare executive qualifies him to serve as a member of our board of directors.
Christopher C. Dewey serves as our Chief Executive Officer and is a member of the board of directors . He has significant experience with medical devices and has been a Managing Director of Ceros Financial Services, Inc., an investment advisory firm, since 2019. Mr. Dewey was a founding board member of MAKO Surgical Corp., a transformational robotic surgical company, where he served on the board from its initial public offering in 2008 until its $1.65 billion sale to Stryker Corp. in 2013 and held positions on the audit and compensation committees. He has been a founding investor and board member of many medical technology startups, including: Auris Surgical Robotics, Inc. from 2012 to 2014, PROCEPT BioRobotics Corp., ShockWave Medical, Inc. (Nasdaq: SWAV) from 2011 to 2014, OrthoSensor, Inc. from 2009 to 2014 and 2019 to present, DermaSensor, Inc. from 2011 to present, Horu Ophthalmics, Inc. from 2019 to present, Cephea Valve Technologies, Inc. from 2013 to 2019, GI Windows Corp., HistoSonics, Inc., Insightec, Ltd. as a board observer from 2019 to present, Magic Leap, Inc., Memic Innovative Surgery, Inc., MIVI Neuroscience, Inc. from 2018 to present, Potrero Medical, Inc., Pristine Surgical, LLC, and TriFlo Cardiovascular Inc. from 2019 to present. From 1966 to 1979, Mr. Dewey was a Founder and President of The Cannon Group, Inc. (i.e., Cannon Films), which was the one of the first independent film companies to finance, produce and distribute motion pictures worldwide. He also has had a successful career on Wall Street serving as Executive Vice President and Head of High Yield Sales at Jefferies & Co. from 1994 until 2007, and subsequently was Vice Chairman of National Securities Corp. from 2007 until 2011. Mr. Dewey was a Partner and Institutional Sales Manager in High Yield Fixed Income at Bear, Stearns & Co. from 1980 to 1990, and Managing Partner of Scully Brothers & Foss/The Marion Group, L.P. until 1994. He holds an MBA from The Wharton Graduate School of Business. Our board has determined that Mr. Dewey’s experience as director of medical technology companies, including public company experience, qualifies him to serve as a member of our board of directors.
David J. Matlin has served on our board of directors and as our Chief Financial Officer since inception. Mr. Matlin is also the co-founder and Chief Executive Officer of MatlinPatterson Global Advisers LLC, or MatlinPatterson, a distressed securities investment manager, which he co-founded in July 2002. Mr. Matlin was also Chief Executive Officer of MatlinPatterson Asset Management L.P. and its operating joint venture affiliates that managed non-distressed credit strategies, from 2015 to 2018. Prior to forming MatlinPatterson, Mr. Matlin was a Managing Director at Credit Suisse, and headed their Global Distressed Securities Group upon its inception in 1994. Mr. Matlin was also a Managing Director and a founding partner of Merrion Group, L.P., an investment advisory firm, from 1988 to 1994. He began his career as a securities analyst at Halcyon Investments from 1986 to 1988. Mr. Matlin has served as a member of the board of directors of Flagstar Bank FSB, a federally charted savings bank, and Flagstar Bancorp, Inc. (NYSE: FBC), a savings and loan holding company since 2009. Since September 2020, he has served on the board of Oceanus LLC, which owns and operates liquified natural gas vessels. Mr. Matlin also serves on the board of directors of US Well Services Inc. (Nasdaq: USWS) (formerly Matlin & Partners Acquisition Corporation) and was Chief Executive Officer and Chairman of the company prior to its business combination with US Well Services LLC. He also serves on the boards of directors of OrthoSensor, Inc., Dermasensor, Inc. and Pristine Surgical LLC, which are medical device manufacturers, Since 2020 he has been an observer of the board of Clene Nanomedicine, Inc. a biopharmaceutical manufacturer, and since 2020 he has served on the board of Traffk, LLC, an insurance-based data analytics company. Previously, he served on the board of directors of CalAtlantic Group, Inc. (NYSE: CAA), a U.S. homebuilder, from 2009 to 2018, Global Aviation Holdings, Inc., an air charter company, from 2006 to 2012, and Huntsman Corporation (NYSE: HUN), a U.S. chemicals manufacturer, between 2005 and 2007. Mr. Matlin holds a JD degree from the Law School of the University of California at Los Angeles and a BS in Economics from the Wharton School of the University of Pennsylvania. Our board has determined that Mr. Matlin’s significant public company board experience qualifies him to serve as a member of our board of directors.
Robert H. Weiss has been our Chief Administrative Officer and Secretary since inception. Mr. Weiss was General Counsel and a Partner of MatlinPatterson Global Advisers LLC and its affiliates from 2002 until 2020. Prior to joining MatlinPatterson in 2002, Mr. Weiss was a Managing Director at Deutsche Asset Management, where he was responsible for hedge fund and fund-of-funds administration, accounting, and product-related legal and compliance functions from 1996 to 2002. From 1991 to 1996, Mr. Weiss was General Counsel to Moore Capital Management, Inc. and Senior Vice President within the futures and managed futures business of Lehman Brothers from 1989 to 1991, as well as Associate General Counsel from 1986 to 1989. Mr. Weiss began his career in the legal department of futures commission merchant Johnson Matthey & Wallace, Inc. in 1983. Mr. Weiss holds a JD degree from Hofstra Law School and an AB cum laude in Political Science from Vassar College.
Maurice R. Ferré, MD will serve as our director upon the effective date of the registration statement of which this prospectus forms part. Dr. Ferré is also the Chief Executive Officer and Chairman of the Board of Insightec Ltd., an innovator of incisionless surgery, a role he has held since January 2015. Dr. Ferré brings over 20 years of experience as a serial entrepreneur in the medical technology industry. From 2004 to 2014, Dr. Ferré served as Chief Executive Officer and Chairman of the Board of MAKO Surgical Corporation, a transformational robotic surgical company that he co-founded. The company was later acquired by Stryker Corp in 2013. Prior to that, Dr. Ferré was founder, Chief Executive Officer and President of Visualization Technology Inc. (“VTI”) from 1993 to 2003. VTI became a world leader in image-guided surgery with a navigation platform for ENT and was acquired by GE Healthcare. Dr. Ferré received his Doctor of Medicine and Master of Public Health from Boston University in 1992. He was the recipient of the Ernst & Young 2007 Entrepreneur of the Year Award and was awarded BioFlorida’s Lifetime Achievement Award in 2018. Dr. Ferré is a member of the Board of Trustees for Boston University and is also active on the boards of The Everglades Foundation and Endeavor Miami. Our board has determined that Dr. Ferré’s experience as a director at medical technology companies qualifies him to serve as a member of our board of directors.
Ivan Delevic will serve as our director upon the effective date of the registration statement of which this prospectus forms part. He brings a wealth of medical device industry experience from his 25 years with Johnson & Johnson (NYSE: JNJ), GE Healthcare, and MAKO Surgical Corp., a transformational robotic surgical company, where he served as Senior Vice President of Corporate Development from 2009 until its $1.65 billion sale to Stryker Corp. in 2013. Mr. Delevic has served the Chief Executive Officer and President of OrthoSensor, Inc., a leader in orthopedic sensor technologies, since October 2014 and a director of the board of director of OrthoSensor, Inc. since 2015. He previously served in several capacities at GE Healthcare from 1996 to 2007, including General Manager of Molecular Imaging EMEA, Global Marketing and Sales VP for Surgical Navigation. Mr. Delevic holds board positions at several medical device and healthcare companies, including: Insightec Ltd. (since 2014), DermaSensor Inc. (since 2015), Pristine Surgical Corp. (since 2017) and EnMovi Ltd. (since 2019). Mr. Delevic holds an MBA from the Technical University of Budapest through a joint program with Herriot-Watt University and a M.Sc. in Electrical Engineering from the Technical University of Budapest. Our board has determined that Mr. Delevic’s experience serving on boards of medical device companies qualifies him to serve as a member of our board of directors.
Martin W. Roche, MD will serve as our director upon the effective date of the registration statement of which this prospectus forms part. He is a practicing orthopedic surgeon specializing in robotic and sensor assisted knee surgery at Holy-Cross Hospital in Fort Lauderdale, Florida since 1996, and is Director of Arthroplasty for the “Hospital for Special Surgery Florida” . He serves as a member of the American and European Knee Society. Dr. Roche was the designing surgeon and performed the first robotic assisted Makoplasty partial and total knee arthroplasty. He has published and lectured extensively in the field of orthopedics and holds over 100 patents focused on medical technology. He is the founder of OrthoSensor, Inc. and has served as its Chief Medical Officer and director since 2008. He is a consultant to Stryker Orthopedics and Pristine Surgical, LLC. He received his MD in Biology from University College Cork in Ireland, and completed his Orthopedic Residency at Jackson Memorial Hospital in Miami, Florida. Our board has determined that Dr. Roche’s expertise in the medical technology field and director experience qualifies him to serve as a member of our board of directors.